For presentation to the Authorities of Moldavia

Declaration

Dear Sir / Madam,

We, Roche Diagnostics GmbH, Mannheim, Federal Republic of Germany herewith confirm that the products which are placed on the market in the sense of Directive 98/79/EEC in the EEA and which bear the CE-mark comply with this mentioned directive. This statement is true for the following products:

- Clinical Chemistry (Hitachi instruments, Hitachi system reagents, Hitachi HIA reagents, Integra instruments, Integra system reagents, Integra HIA reagents, laboratory integration hardware, cobas 6000, cobas c 501 and 502 system, cobas c 501 and 502 system reagents)
- Immunodiagnostics (Cobas Core instruments and reagents, Elecsys instruments and reagents, cobas 6000, cobas 8000 cobas e 601 and 602 system, cobas e 601 and 602 system reagents)
- Urinanalysis (Miditron, Urisys 1100 and cobas u411 instruments and strips)
- Bloodgas analysis (9180, cobas b 121, cobas b 221, cobas b 123 analyzer and system reagents)
- Near-Patient Testing (Primary Care, Hospital POC, Coagulation monitoring, consumer products, cobas 101 analyzer and reagents)

Mannheim, July 19, 2013

Roche Diagnostics GmbH
i.V. i.V.

Dr. Bayer S. Grigarrczik

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49 621 759 0; Telefax +49 621 759 2890

Sitz der Gesellschaft: Mannheim - Registergericht: AG Mannheim, HRB 3962 - Geschäftsführung: Thomas Schmid, Sprecher; Edgar Vieth - Aufsichtsratsvorsitzender: Dr. Severin Schwan